Trieza Therapeutics is a new company developing immunomodulatory oncolytic viruses for the treatment of cancer. Founded as a spin-out from Potenza Therapeutics, Trieza has a portfolio containing multiple pre-clinical candidates.
Trieza Therapeutics, Inc.
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Website
Founded2016
Disease Focus
Development Stage
STOCK CODENon Listed
Address1030 Massachusetts Avenue Suite 210, MA, 02138CambridgeUnited States
1030 Massachusetts Avenue Suite 210, MA, 02138
Cambridge
United States
Contact Number
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
Trieza Therapeutics, is developing immunomodulatory oncolytic viruses that attack cancer cells.
In Dec 2016, Abzena PLC has granted Trieza an exclusive worldwide, royalty-bearing licence to an undisclosed antibody sequence,
created using Abzenas Composite Human Antibody technology. Under the terms, Abzena will receive up to USD35.0 Mn in development and commercial milestone, plus further royalties on the sale of licensed products.